SBIA
CLVS

Sheaff Brock Investment Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,351
Closed -$83K – 572
2021
Q2 		$83K Buy
14,351
+2,500
+21% +$14.6K 0.01% 512
2021
Q1 		$84K Buy
+11,851
New +$79.5K 0.01% 487
2020
Q4 		– Sell
-14,591
Closed -$85K – 518
2020
Q3 		$85K Buy
14,591
+3,000
+26% +$17.9K 0.01% 436
2020
Q2 		$78K Sell
11,591
-2,010
-15% -$15.2K 0.01% 431
2020
Q1 		$87K Buy
+13,601
New +$109K 0.01% 380
2018
Q3 		– Sell
-4,446
Closed -$202K – 568
2018
Q2 		$202K Sell
4,446
-2,780
-38% -$135K 0.02% 465
2018
Q1 		$382K Buy
7,226
+850
+13% +$49.6K 0.04% 310
2017
Q4 		$434K Buy
6,376
+1,476
+30% +$103K 0.06% 283
2017
Q3 		$404K Buy
4,900
+675
+16% +$53.5K 0.05% 299
2017
Q2 		$396K Buy
4,225
+700
+20% +$42.8K 0.05% 325
2017
Q1 		$224K Buy
+3,525
New +$214K 0.03% 477

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sheaff Brock Investment Advisors's CLVS Position: Q3 2021 in Review

Sheaff Brock Investment Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q3 2021, closing a stake of 14,351 shares — an estimated $83K sold.

Sheaff Brock Investment Advisors first reported a position in CLVS in Q1 2017 and held it in 11 quarters. The position peaked at $434K in Q4 2017. 157 funds tracked by Wall St. Rank hold CLVS as of Q3 2021.

  • Sheaff Brock Investment Advisors reported no remaining Clovis Oncology, Inc. position as of Q3 2021 after selling out during the quarter.
  • Sheaff Brock Investment Advisors sold 14,351 Clovis Oncology, Inc. shares in Q3 2021, an estimated $83K.
  • Sheaff Brock Investment Advisors first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 11 quarters.
  • Sheaff Brock Investment Advisors's Clovis Oncology, Inc. position peaked at $434K in Q4 2017.
  • 157 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2021.

Based on Sheaff Brock Investment Advisors's 13F filing for Q3 2021, filed 3 Nov 2021.